|
|
|
|
| |
|
Newsletter Sponsor
|
|
Better Oncology Bioavailability with Amorphous Solid Dosage Forms
Solubility in the GI tract can be a real problem for oral tyrosine kinase inhibitors used to treat cancer, as it is often pH dependent. By formulating the drug as an amorphous solid dispersion, its sensitivity to pH variability can be reduced, while still retaining the convenience of an oral dosage form. A recent whitepaper by Lonza’s Deanna Mudie explains how the strategy can be used to create more effective, patient-friendly drug products.
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Featured Products |
 |
|
| |
|
|
|
Lasair Pro
Particle Measuring Systems
The Lasair Pro supports a complete contamination control solution including clean area monitoring (...
learn more » |
 |
 |
|
|
|
|
|
|
|
|
 |
| |
|
|
|
|
|
More Products
|
|
|
|
|
1290 Infinity II Refractive Index Detector Learn More
BioFlo 120 Single-Use Bioreactor Learn More
Aeris Research Benchtop X-Ray Diffractometer Learn More
|
|
|
|
|
|
| |
|
Events |
|
|
| |
|
|
Pittcon 2024
San Diego, CA – 02/24/2024
Pittcon is a dynamic, transnational conference and exposition on laboratory science, a venue for presenting the latest advances in analytical research...
event details » |
|
|
|
|
|
Global Bioprocessing Summit
Berlin, Germany – 11/16/2023
The industry, professionals, and scientists are actively seeking methods to delineate more precise guidelines and anticipated requirements for ...
event details » |
|
|
|
 |
|
|
